Seladelpar lysine is a small molecule commercialized by Gilead Sciences, with a leading Pre-Registration program in Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to Globaldata, it is involved in 16 clinical trials, of which 10 were completed, 3 are ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Seladelpar lysine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Seladelpar lysine is expected to reach an annual total of $450 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Seladelpar lysine Overview

Seladelpar lysine (MBX-8025, RWJ-800025) is under development for the treatment of primary biliary cholangitis (PBC), liver fibrosis, primary sclerosing cholangitis (PSC). The drug candidate is administered through the oral route as a capsule. MBX-8025 targets human PPAR-delta receptor. It was under development for the treatment of Fredrickson types I and V hyperlipoproteinemias, non-alcoholic steatohepatitis (NASH), mixed dyslipidemia, severe hypertriglyceridemia (SHTG) and homozygous familial hypercholesterolemia (HoFH).

Gilead Sciences Overview

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, cancer, and human immunodeficiency virus (HIV) infection. It markets its products through commercial teams, third-party distributors and corporate partners. Gilead’s commercial teams promote its products through direct field contact with physicians, hospitals, clinics and other healthcare providers. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.
The company reported revenues of (US Dollars) US$27,116 million for the fiscal year ended December 2023 (FY2023), a decrease of 0.6% over FY2022. In FY2023, the company’s operating margin was 28%, compared to an operating margin of 26.9% in FY2022. In FY2023, the company recorded a net margin of 20.9%, compared to a net margin of 16.8% in FY2022. The company reported revenues of US$6,686 million for the first quarter ended March 2024, a decrease of 6% over the previous quarter.

For a complete picture of Seladelpar lysine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.